Examiner Cite

No

Initial*

S

Patent Number

Kind

publisher, city and/or country where published.

Code1

Issue Date

Remove

Figures Appear

Pages.Columns.Lines where

Relevant Passages or Relevant

Τ۶

	Application Number		10580131		
	Filing Date		2008-07-18		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor GODD		DARD, LAURA B		
	Art Unit		1642		
	Examiner Name	GODDARD, LAURA B.			
	Attornov Docket Number		05 1037 AS		

U.S. PATENTS

Name of Patentee or Applicant

of cited Document

	1										
If you wis	h to a	dd a	idditional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
				U.S.P	ATENT	APPLK	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite	No	Publication Number	Kind Code ¹	Publica Date	ition	of cited Decument Rek		Rele	ges,Columns,Lines where levant Passages or Relevan ures Appear	
	1									_ ^ _	
If you wisl	h to a	dd a	idditional U.S. Publi	shed Ap	plication	citation	ninformation	please click the Ad	d butto		
					FOREIG	SN PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No		reign Document imber ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	тя
	1										
If you wis	h to a	dd a	dditional Foreign Pa	atent Do	cument	citation	information p	lease click the Add	butto	n Add	_
				NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	

NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s),

Examiner Cite

Initials* No

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10580131		
Filing Date		2008-07-18		
First Named Inventor	GODE	DARD, LAURA B		
Art Unit		1642		
Examiner Name	GODE	DARD, LAURA B.		
Attornou Docket Number		05.1037-45		

	1	GenBank Reference No. 21361432 (NM_014264.2) entitled: "Homo sapiens polo-like knase 4 (Drosophila) (PLK4), mRNA," dated October 5, 2003.				
	2	GenBank Reference No. 7657626 (NM_014264.1) entitled: "Homo sapiens sennethreonine innase 18 (STK18), mRNA, "dated November 2, 2000.				
	3	GenBank Reference No. 14721506 (XM_033920.1) entitled: "Homo sapiens semne/threonne kinase 18 (STK18), mRNA," dated May 13, 2002.				
	4	GenBank Reference No. 16215695 (AB006972.1) entitled: "Homo saprens mRNA for Saix, complete cds," dated October 18, 2001.				
	5	GenBank Reference No. 23243308 (BIC039023.1) entitled: "Homo sapiens polo-like kinase 4 (Drosophila), mRNA (cDNA done MGC:33045 MAGE:5273226), complete cds, "dated November 12, 2003.				
	6	GenBank Reference No. 2136/432 (NM_014264.2) entitled: "Homo sapiens polo-like kinase 4 (Drosophila) (PLK4), mRNA," dated October 5, 2003.				
	7	GenBank Reference No. 21361433 (NP_055079.2) entitled: "polo-like lunsse 4 [Homo saprens]," dated October 5, 2003.				
If you wish to add additional non-patent literature document citation information please click the Add button Add						
EXAMINER SIGNATURE						

Examiner Signature | Date Considered |

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See find. Codes of USPTO Petent Documents at sever USPTO COV or MEPP 90.104. * Enter disc that issued the document, by the Voicitien code (WIPO Standard ST.3.) * For Laplanese petent for comments, the indication of the year of the region of the Emperor many precised the serial number of the petent format of the petent form

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10580131
Filing Date			2008-07-18
First Named Inventor GODE			DARD, LAURA B
Art Unit			1642
	Examiner Name	GODE	DARD, LAURA B.
Attorney Docket Number			05-1037-A5

CERTIFICATION STATEMENT

Please see 37	7 CFR 1.97	and 1.98 to	make the appro	priate selection(s	3):
---------------	------------	-------------	----------------	--------------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97.0Fet. 97/e(vf.)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Anita J. Terpstra/	Date (YYYY-MM-DD)	2011-09-21
Name/Print	Anita J. Ternstra	Registration Number	47132

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.